ASMB Terminates Material Agreement, Signals Strategic Shift

TL;DR

**ASMB just terminated a key agreement, watch for details on what's next.**

AI Summary

Assembly Biosciences, Inc. (ASMB) filed an 8-K on January 17, 2024, reporting the termination of a material definitive agreement, effective January 11, 2024. This termination could signal a shift in the company's strategic partnerships or product development plans, which might impact future revenue streams or operational costs. Investors should monitor for further announcements regarding the reasons for termination and any new agreements, as this could affect the company's valuation and growth prospects.

Why It Matters

The termination of a material agreement can significantly alter a company's financial outlook, potentially impacting its revenue, expenses, and future product pipeline. Investors need to understand the implications for Assembly Biosciences' long-term strategy and profitability.

Risk Assessment

Risk Level: medium — The termination of a material agreement introduces uncertainty regarding future business operations and financial performance, posing a moderate risk to investors.

Analyst Insight

A smart investor would seek further information from Assembly Biosciences regarding the specific agreement terminated and the reasons behind it, as well as any potential impact on their product pipeline or financial projections, before making investment decisions.

Key Players & Entities

• Assembly Biosciences, Inc. (company) — the registrant filing the 8-K
• January 11, 2024 (date) — date of the earliest event reported (termination effective date)
• January 17, 2024 (date) — date the 8-K was filed
• ASMB (company) — trading symbol for Assembly Biosciences, Inc.
• The Nasdaq Global Select Market (company) — exchange where ASMB Common Stock is registered

FAQ

From the Filing

0000950170-24-005024.txt : 20240117 0000950170-24-005024.hdr.sgml : 20240117 20240117160509 ACCESSION NUMBER: 0000950170-24-005024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20240111 ITEM INFORMATION: Termination of a Material Definitive Agreement FILED AS OF DATE: 20240117 DATE AS OF CHANGE: 20240117 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASSEMBLY BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001426800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35005 FILM NUMBER: 24538434 BUSINESS ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (833) 409-4583 MAIL ADDRESS: STREET 1: TWO TOWER PLACE STREET 2: 7TH FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: VENTRUS BIOSCIENCES INC DATE OF NAME CHANGE: 20080211 8-K 1 asmb-20240111.htm 8-K 8-K false 0001426800 0001426800 2024-01-11 2024-01-11     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Assembly Biosciences, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35005 20-8729264 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)       Two Tower Place , 7th Floor , South San Francisco , California 94080 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (833) 509-4583 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.02 Termination of a Material Definitive Agreement. On January 11, 2024, Assembly Biosciences, Inc. (the "Company") notified the Indiana University Innovation and Commercialization Office that the Company has decided to terminate the Exclusive License Agreement dated September 3, 2023 by and between Indiana University Research and Technology Corporation ("IURTC") and Assembly Pharmaceuticals, Inc., the Company's predecessor (the "License Agreement"), as amended by Amendment No. 1 to the License Agreement dated February 28, 2017 and Amendment No. 2 to the License Agreement dated July 10, 2020. The termination of the License Agreement will be effect